TrialRheumatology (Oxford, England)2022

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis.

Daniel E Furst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.